The multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.
Multi-institution analysis identifies a new chromosomal abnormality linked to enzalutamide resistance.
Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.
Antiandrogen treatment is associated with heart and neurological problems and didn’t increase survival for this group of men, a U-M analysis finds.
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline health care workers.
Researchers characterize three ways in which the gene FOXA1 mutates to trigger prostate cancer.